$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000119312515375659 Filed on November 12, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.230M	$2.190M	$1.700M
YoY Change	17.37%	28.82%	126.67%
% of Gross Profit
Research & Development	$5.770M	$5.848M	$13.24M
YoY Change	25.98%	-55.82%	271.83%
% of Gross Profit
Depreciation & Amortization	$430.0K	$414.0K	$169.0K
YoY Change	72.0%	144.97%	-6.11%
% of Gross Profit
Operating Expenses	$8.000M	$8.039M	$14.94M
YoY Change	23.46%	-46.19%	246.64%
Operating Profit		-$8.039M	-$14.94M
YoY Change		-46.19%
Interest Expense	-$20.00K	$23.00K	$19.00K
YoY Change	-100.27%	21.05%	-93.87%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	-$39.00K	$2.966M
YoY Change	-150.0%	-101.31%	-29760.0%
Pretax Income	-$8.350M	-$8.080M	-$11.97M
YoY Change	-1007.61%	-32.5%	199.25%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$8.350M	-$8.078M	-$11.97M
YoY Change	-288.06%	-32.54%	199.35%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$37.95M	-$36.73M	-$66.50M
COMMON SHARES
Basic Shares Outstanding	13.27M shares	0.000 shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.92M	$37.72M	$3.260M
YoY Change	-47.17%	1057.06%	-19.9%
Cash & Equivalents	$30.92M	$37.72M	$3.258M
Short-Term Investments
Other Short-Term Assets	$195.0K	$370.0K	$3.110M
YoY Change	33.56%	-88.1%	1627.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$31.24M	$38.09M	$6.370M
YoY Change	-47.35%	497.93%	49.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.213M	$5.513M	$3.380M
YoY Change	6.87%	63.11%	39.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$140.0K	$1.190M	$1.680M
YoY Change	-82.28%	-29.17%	211.11%
Total Long-Term Assets	$5.550M	$7.213M	$5.630M
YoY Change	-10.14%	28.12%	56.39%
TOTAL ASSETS
Total Short-Term Assets	$31.24M	$38.09M	$6.370M
Total Long-Term Assets	$5.550M	$7.213M	$5.630M
Total Assets	$36.79M	$45.30M	$12.00M
YoY Change	-43.84%	277.51%	52.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.024M	$2.001M	$4.360M
YoY Change	-58.58%	-54.11%	111.65%
Accrued Expenses	$1.444M	$2.449M	$1.630M
YoY Change	-13.84%	50.25%	482.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$10.00M
YoY Change		-100.0%
Long-Term Debt Due	$580.0K	$580.0K	$90.00K
YoY Change	41.46%	544.44%
Total Short-Term Liabilities	$6.359M	$6.690M	$17.58M
YoY Change	-16.33%	-61.95%	525.62%
LONG-TERM LIABILITIES
Long-Term Debt	$760.0K	$910.0K	$370.0K
YoY Change	-43.7%	145.95%
Other Long-Term Liabilities	$1.470M	$1.530M	$25.49M
YoY Change	-13.53%	-94.0%	286.8%
Total Long-Term Liabilities	$2.230M	$2.440M	$25.86M
YoY Change	-26.89%	-90.56%	292.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.359M	$6.690M	$17.58M
Total Long-Term Liabilities	$2.230M	$2.440M	$25.86M
Total Liabilities	$8.588M	$9.125M	$43.44M
YoY Change	-23.95%	-78.99%	362.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$165.6M	-$157.2M
YoY Change	23.98%
Common Stock	$193.8M	$193.4M
YoY Change	3.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.20M	$36.18M	-$31.45M
YoY Change
Total Liabilities & Shareholders Equity	$36.79M	$45.30M	$12.00M
YoY Change	-43.84%	277.51%	52.87%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$8.350M	-$8.078M	-$11.97M
YoY Change	-288.06%	-32.54%	199.35%
Depreciation, Depletion And Amortization	$430.0K	$414.0K	$169.0K
YoY Change	72.0%	144.97%	-6.11%
Cash From Operating Activities	-$6.990M	-$6.880M	-$2.790M
YoY Change	49.36%	146.59%	-23.77%
INVESTING ACTIVITIES
Capital Expenditures	-$130.0K	-$500.0K	-$1.390M
YoY Change	-92.53%	-64.03%	334.38%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$130.0K	-$500.0K	-$1.390M
YoY Change	-92.53%	-64.03%	334.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-150.0K	-120.0K	-340.0K
YoY Change	-100.24%	-64.71%
NET CHANGE
Cash From Operating Activities	-6.990M	-6.880M	-2.790M
Cash From Investing Activities	-130.0K	-500.0K	-1.390M
Cash From Financing Activities	-150.0K	-120.0K	-340.0K
Net Change In Cash	-7.270M	-7.500M	-4.520M
YoY Change	-113.15%	65.93%	13.57%
FREE CASH FLOW
Cash From Operating Activities	-$6.990M	-$6.880M	-$2.790M
Capital Expenditures	-$130.0K	-$500.0K	-$1.390M
Free Cash Flow	-$6.860M	-$6.380M	-$1.400M
YoY Change	133.33%	355.71%	-58.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	44531	shares
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13273470	shares
CY2012Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	117000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3258000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1226890	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.51
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1131524	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13273470	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.47
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	290014	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	156138	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13273470	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.41
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	193260000
CY2015Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	1147000
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	36176000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	120000
CY2015Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	225000
CY2015Q3	us-gaap	Loans Payable Current LoansPayableCurrent	583000
CY2015Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	381000
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2001000
CY2015Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	907000
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2449000
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157216000
CY2015Q3	us-gaap	Liabilities Liabilities	9125000
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45301000
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	132000
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q3	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	1053000
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7557000
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6690000
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q3	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	379000
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	125000
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4438000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	3955000
CY2015Q3	us-gaap	Assets Assets	45301000
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5513000
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	137000
CY2015Q3	us-gaap	Noncurrent Assets NoncurrentAssets	5513000
CY2015Q3	us-gaap	Assets Current AssetsCurrent	38088000
CY2015Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	31750000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	630000
CY2015Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	510000
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	365000
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37723000
CY2015Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	1053000
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13070000
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12755012	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4361000
CY2015Q3	hsgx	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	4.68
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8734000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	537683	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.19
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	156138	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12755012	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	187620000
CY2014Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	1318000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	54206000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	120000
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	219000
CY2014Q4	us-gaap	Loans Payable Current LoansPayableCurrent	405000
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	379000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4886000
CY2014Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	1345000
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1683000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133541000
CY2014Q4	us-gaap	Liabilities Liabilities	11293000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65499000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	127000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	651000
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6375000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8251000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	407000
CY2014Q4	us-gaap	Assets Assets	65499000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4878000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	604000
CY2014Q4	us-gaap	Noncurrent Assets NoncurrentAssets	4878000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	58856000
CY2014Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	49750000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	630000
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11253000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	510000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	796000
CY2014Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	5158407	shares
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58060000
CY2014Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	651000
CY2014Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	70115000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13260000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0107	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0183	pure
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-45.49
CY2014Q4	hsgx	Proceeds From Issuance Initial Public Offering Net ProceedsFromIssuanceInitialPublicOfferingNet	61277000
CY2014Q4	hsgx	Class Of Warrant Or Right Number Of Securities Surrendered ClassOfWarrantOrRightNumberOfSecuritiesSurrendered	5839	shares
CY2012Q3	hsgx	Class Of Warrant Or Right Exercisable Expiration Period ClassOfWarrantOrRightExercisableExpirationPeriod	P10Y
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P2Y8M19D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.952	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.045	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.74
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	598684	shares
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	1443000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1577000
	us-gaap	Net Income Loss NetIncomeLoss	-23713000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	172000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	73000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26123000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2410000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	79000
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2435000
	us-gaap	Share Based Compensation ShareBasedCompensation	356000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	608000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5476000
	us-gaap	Operating Expenses OperatingExpenses	26123000
	us-gaap	Interest Expense InterestExpense	19000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1577000
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	10314000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9361000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21280000
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	464000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	594000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	356000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4843000
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	-39000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1993000
	us-gaap	Depreciation Depreciation	482000
	hsgx	Deferred Rent And Lease Incentive DeferredRentAndLeaseIncentive	-247000
	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-27233000
	hsgx	Non Cash Consideration For Licensed Technology NonCashConsiderationForLicensedTechnology	10000000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>1. NATURE OF BUSINESS</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Organization</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Histogenics Corporation (the “Company”) is a Delaware corporation and has its principal operations in Waltham, Massachusetts. The Company is a regenerative medicine company engaged in developing and commercializing products in the musculoskeletal segment of the marketplace. The Company is developing technology and products to treat cartilage damage, including NeoCart for the repair of cartilage lesions. NeoCart is currently in a Phase 3 clinical trial in the United States under a special protocol assessment with the U.S. Food and Drug Administration (“FDA”) for the treatment of knee cartilage damage.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Since its inception, the Company has devoted substantially all of its efforts to product development, recruiting management and technical staff, raising capital, starting up production and building infrastructure and has not generated revenues from its planned principal operations. Expenses have primarily been for research and development and administrative costs.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The Company is subject to a number of risks. Principal among these risks are: the successful development of its products, successfully enrolling patients in its clinical trials in a timely manner, protection of its intellectual property, obtaining FDA approval for its products and maintaining ongoing compliance with government regulations, the ability to obtain adequate financing, fluctuations in operating results, dependence on key personnel and collaborative partners, adoption of the Company’s products by the physician community, rapid technological changes inherent in the markets targeted, and substitute products and competition from larger companies.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Initial public offering</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> On December 8, 2014, the Company closed its initial public offering (“IPO”) whereby the Company sold 5,909,091 shares of common stock at a price of $11.00 per share for gross proceeds of $65,000. The shares began trading on The Nasdaq Global Market on December 3, 2014. On January 6, 2015, an additional 465,000 shares of common stock were sold at the IPO price of $11.00 per share following the underwriters’ exercise in part of their overallotment option for gross proceeds of $5,115. Gross proceeds from the offering, inclusive of the overallotment, were $70,115. After giving effect to underwriting discounts and commissions and offering expenses payable by the Company, net proceeds were $61,277. In addition, each of the following occurred in connection with the completion of the IPO on December 8, 2014:</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">the conversion of all outstanding shares of the Company’s convertible redeemable preferred stock and accrued dividends into 5,158,407 shares of common stock;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">the conversion of $11,100 in convertible notes payable and accrued interest into 1,009,115 shares of common stock;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">the net exercise of certain warrants into 44,531 shares of common stock and the surrender of 5,839 warrant shares to satisfy the contingent payment payable to Purpose Co., Ltd. (“Other Liability”), resulting in the settlement of the related warrant liability and Other Liability upon the closing of the IPO of $490 and $612, respectively, to additional paid-in capital;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">the termination of the redemption provision of the net sales distribution payment; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">the authorization to issue 100,000,000 shares of common stock and 10,000,000 shares of preferred stock.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Basis of Presentation and Principles of Consolidation</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The condensed consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These interim condensed consolidated financial statements, in the opinion of the Company’s management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods ended September 30, 2015 and 2014. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2014, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2015.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The condensed consolidated financial statements include the accounts of Histogenics Corporation and its wholly-owned subsidiaries, ProChon Biotech Ltd. (“ProChon”) and Histogenics Securities Corporation. All intercompany accounts and transactions are eliminated in consolidation.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-23037000
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.628	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.67
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	Histogenics Corporation
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y15D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0166	pure
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	121057	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.79
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P5Y9M22D
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.633	pure
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	863722	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Reclassifications</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has reclassified certain prior period amounts to conform to the current period presentation. The amounts reclassified impact research and development expenses and general and administrative expenses for the three months and nine months ended September 30, 2014.</p> </div>
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.55
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	53458	shares
	us-gaap	Interest Expense InterestExpense	111000
	dei	Trading Symbol TradingSymbol	HSGX
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13218765	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y2M12D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1818000
	us-gaap	Net Income Loss NetIncomeLoss	-23675000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	260000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-431000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	73000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23505000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-170000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-467000
	us-gaap	Share Based Compensation ShareBasedCompensation	854000
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	857000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-20337000
	us-gaap	Operating Expenses OperatingExpenses	23505000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1818000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4518000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17470000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4738000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	766000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	40000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	854000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6035000
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	14000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2885000
	us-gaap	Depreciation Depreciation	1182000
	hsgx	Deferred Rent And Lease Incentive DeferredRentAndLeaseIncentive	-191000
	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-23675000
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2014Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0095	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0178	pure
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-19.38
CY2014Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P2Y11M19D
CY2014Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.982	pure
CY2014Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.044	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.29
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	617860	shares
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-11974000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14940000
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2966000
CY2014Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2986000
CY2014Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	275000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	14940000
CY2014Q3	us-gaap	Interest Expense InterestExpense	19000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13237000
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	168000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1703000
CY2014Q3	us-gaap	Depreciation Depreciation	169000
CY2014Q3	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-11974000
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2015Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0179	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0173	pure
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2015Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P7Y5M23D
CY2015Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.608	pure
CY2015Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.601	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	0	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.22
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13238997	shares
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-8078000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8039000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-39000
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	266000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	8039000
CY2015Q3	us-gaap	Interest Expense InterestExpense	23000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5848000
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	362000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2191000
CY2015Q3	us-gaap	Depreciation Depreciation	414000
CY2015Q3	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-8078000

Files In Submission

Name	View Source	Status
0001193125-15-375659-index-headers.html	Edgar Link	pending
0001193125-15-375659-index.html	Edgar Link	pending
0001193125-15-375659.txt	Edgar Link	pending
0001193125-15-375659-xbrl.zip	Edgar Link	pending
d35240d10q.htm	Edgar Link	pending
d35240dex311.htm	Edgar Link	pending
d35240dex312.htm	Edgar Link	pending
d35240dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hsgx-20150930.xml	Edgar Link	completed
hsgx-20150930.xsd	Edgar Link	pending
hsgx-20150930_cal.xml	Edgar Link	unprocessable
hsgx-20150930_def.xml	Edgar Link	unprocessable
hsgx-20150930_lab.xml	Edgar Link	unprocessable
hsgx-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2015 Q4 Form 10-Q Financial Statement

#000119312515375659 Filed on November 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2015 Q4 Form 10-Q Financial Statement

#000119312515375659 Filed on November 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn